S1607 Assessing the Risk of Post-ERCP Pancreatitis and other ERCP Complications Among Patients Given Prophylactic Oral Tacrolimus

Sanya Goswami,Rahul Raiker,Haig Pakhchanian,Amar Manvar,Jessica Widmer
DOI: https://doi.org/10.14309/01.ajg.0001035796.59541.8a
2024-10-26
The American Journal of Gastroenterology
Abstract:Post-ERCP pancreatitis (PEP) is the most common adverse event of endoscopic retrograde cholangiopancreatography (ERCP). In 2023, ASGE released guidelines recommending aggressive hydration, rectal NSAIDS, and prophylactic pancreatic stenting to prevent PEP. Experimental mice model studies have shown administration of rectal tacrolimus as a critical mediator of PEP. This study examines the risk of PEP and other ERCP complications among patients given oral tacrolimus versus rectal indomethacin or no prophylactic drug.
gastroenterology & hepatology
What problem does this paper attempt to address?